|
|
Blood, 1 January 2005, Vol. 105, No. 1, pp. 251-258.
Prepublished online as a Blood First Edition Paper on August 24, 2004; DOI 10.1182/blood-2004-04-1422.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
Ennio Carbone,
Paola Neri,
Maria Mesuraca,
Mariateresa T. Fulciniti,
Takemi Otsuki,
Daniela Pende,
Veronika Groh,
Thomas Spies,
Giuditta Pollio,
David Cosman,
Lucio Catalano,
Pierfrancesco Tassone,
Bruno Rotoli, and
Salvatore Venuta
From the Dipartimento di Medicina Sperimentale e Clinica " G. Salvatore," Università degli Studi di Catanzaro "Magna Graecia," Catanzaro, Italy; the Microbiology and Tumorbiology Center, Karolinska Institutet, Stockholm, Sweden; the Department of Hygiene, Kawasaki Medical School, Okayama, Japan; the Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; the Fred Hutchinson Cancer Research Center, Seattle, WA; the Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Napoli "Federico II," Napoli, Italy; and Amgen, Seattle, WA.
The role of natural killer (NK) cells in multiple myeloma is not fully understood. Here, NK susceptibility of myeloma cells derived from distinct disease stages was evaluated in relation to major histocompatibility complex (MHC) class I, MHC class I chain-related protein A (MICA), MHC class I chain-related protein B (MICB), and UL16 binding protein (ULBP) expression. MHC class I molecules were hardly detectable on bone marrow cells of early-stage myeloma, while late-stage pleural effusion-derived cell lines showed a strong MHC class I expression. Conversely, a high MICA level was found on bone marrow myeloma cells, while it was low or not measurable on pleural effusion myeloma cells. The reciprocal surface expression of these molecules on bone marrow- and pleural effusion-derived cell was confirmed at mRNA levels. While bone marrow-derived myeloma cells were readily recognized by NK cells, pleural effusion-derived lines were resistant. NK protection of pleural effusion cells was MHC class I dependent. Receptor blocking experiments demonstrated that natural cytotoxicity receptor (NCR) and NK receptor member D of the lectinlike receptor family (NKG2D) were the key NK activating receptors for bone marrow-derived myeloma cell recognition. In ex vivo experiments patient's autologous fresh NK cells recognized bone marrow-derived myeloma cells. Our data support the hypothesis that NK cell cytotoxicity could sculpture myeloma and represents an important immune effector mechanism in controlling its intramedullary stages. (Blood. 2005;105:251-258)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Alici, T. Sutlu, B. Bjorkstrand, M. Gilljam, B. Stellan, H. Nahi, H. C. Quezada, G. Gahrton, H.-G. Ljunggren, and M. S. Dilber
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Blood,
March 15, 2008;
111(6):
3155 - 3162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jinushi, M. Vanneman, N. C. Munshi, Y.-T. Tai, R. H. Prabhala, J. Ritz, D. Neuberg, K. C. Anderson, D. R. Carrasco, and G. Dranoff
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
PNAS,
January 29, 2008;
105(4):
1285 - 1290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M. El-Sherbiny, J. L. Meade, T. D. Holmes, D. McGonagle, S. L. Mackie, A. W. Morgan, G. Cook, S. Feyler, S. J. Richards, F. E. Davies, et al.
The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells
Cancer Res.,
September 15, 2007;
67(18):
8444 - 8449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Porcu-Buisson, M. Lambert, L. Lyonnet, A. Loundou, M. Gamerre, L. Camoin-Jau, F. Dignat-George, S. Caillat-Zucman, and P. Paul
Soluble MHC Class I chain-related molecule serum levels are predictive markers of implantation failure and successful term pregnancies following IVF
Hum. Reprod.,
August 1, 2007;
22(8):
2261 - 2266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. E. McCann, P. Eissmann, B. Onfelt, R. Leung, and D. M. Davis
The Activating NKG2D Ligand MHC Class I-Related Chain A Transfers from Target Cells to NK Cells in a Manner That Allows Functional Consequences
J. Immunol.,
March 15, 2007;
178(6):
3418 - 3426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Sekimoto, S. Ozaki, T. Ohshima, H. Shibata, T. Hashimoto, M. Abe, N. Kimura, K. Hattori, S. Kawai, Y. Kinoshita, et al.
A Single-Chain Fv Diabody against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment
Cancer Res.,
February 1, 2007;
67(3):
1184 - 1192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Carlsten, N. K. Bjorkstrom, H. Norell, Y. Bryceson, T. van Hall, B. C. Baumann, M. Hanson, K. Schedvins, R. Kiessling, H.-G. Ljunggren, et al.
DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells
Cancer Res.,
February 1, 2007;
67(3):
1317 - 1325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Saikali, J. P. Antel, J. Newcombe, Z. Chen, M. Freedman, M. Blain, R. Cayrol, A. Prat, J. A. Hall, and N. Arbour
NKG2D-Mediated Cytotoxicity toward Oligodendrocytes Suggests a Mechanism for Tissue Injury in Multiple Sclerosis
J. Neurosci.,
January 31, 2007;
27(5):
1220 - 1228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lopez-Soto, A. Quinones-Lombrana, R. Lopez-Arbesu, C. Lopez-Larrea, and S. Gonzalez
Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor
J. Biol. Chem.,
October 13, 2006;
281(41):
30419 - 30430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Zhang, A. Barber, and C. L. Sentman
Generation of Antitumor Responses by Genetic Modification of Primary Human T Cells with a Chimeric NKG2D Receptor
Cancer Res.,
June 1, 2006;
66(11):
5927 - 5933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. von Strandmann, H. P. Hansen, K. S. Reiners, R. Schnell, P. Borchmann, S. Merkert, V. R. Simhadri, A. Draube, M. Reiser, I. Purr, et al.
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
Blood,
March 1, 2006;
107(5):
1955 - 1962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hanaoka, T. Kawaguchi, K. Horikawa, S. Nagakura, H. Mitsuya, and H. Nakakuma
Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP
Blood,
February 1, 2006;
107(3):
1184 - 1191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Karimi, T. M. Cao, J. A. Baker, M. R. Verneris, L. Soares, and R. S. Negrin
Silencing Human NKG2D, DAP10, and DAP12 Reduces Cytotoxicity of Activated CD8+ T Cells and NK Cells
J. Immunol.,
December 15, 2005;
175(12):
7819 - 7828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Altun, P. J. Galardy, R. Shringarpure, T. Hideshima, R. LeBlanc, K. C. Anderson, H. L. Ploegh, and B. M. Kessler
Effects of PS-341 on the Activity and Composition of Proteasomes in Multiple Myeloma Cells
Cancer Res.,
September 1, 2005;
65(17):
7896 - 7901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Geffroy-Luseau, A. Moreau-Aubry, R. Bataille, and C. Pellat-Deceunynck
Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells
Int. Immunol.,
September 1, 2005;
17(9):
1193 - 1200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Girlanda, C. Fortis, D. Belloni, E. Ferrero, P. Ticozzi, C. Sciorati, M. Tresoldi, A. Vicari, T. Spies, V. Groh, et al.
MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated {gamma}{delta} Lymphocytes
Cancer Res.,
August 15, 2005;
65(16):
7502 - 7508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
